Luke Sergott
Stock Analyst at Barclays
(2.13)
# 2,684
Out of 4,829 analysts
277
Total ratings
38.1%
Success rate
-6.99%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NTRA Natera | Maintains: Overweight | $160 → $190 | $151.95 | +25.04% | 3 | May 9, 2025 | |
| CERT Certara | Upgrades: Overweight | $11 → $14 | $11.98 | +16.86% | 17 | May 8, 2025 | |
| CRL Charles River Laboratories International | Maintains: Equal-Weight | $145 → $155 | $138.79 | +11.68% | 6 | May 8, 2025 | |
| BRKR Bruker | Maintains: Overweight | $50 → $46 | $37.52 | +22.60% | 4 | May 8, 2025 | |
| IQV IQVIA Holdings | Maintains: Equal-Weight | $170 → $165 | $148.99 | +10.75% | 22 | May 7, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Equal-Weight | $165 → $155 | $133.96 | +15.71% | 19 | May 2, 2025 | |
| EXAS Exact Sciences | Maintains: Overweight | $55 → $75 | $51.63 | +45.26% | 4 | May 2, 2025 | |
| GH Guardant Health | Maintains: Overweight | $55 → $60 | $41.72 | +43.82% | 3 | May 1, 2025 | |
| AVTR Avantor | Maintains: Overweight | $18 → $15 | $12.02 | +24.79% | 24 | Apr 28, 2025 | |
| DHR Danaher | Maintains: Overweight | $205 → $215 | $189.73 | +13.32% | 39 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $400 → $350 | $344.06 | +1.73% | 18 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $58 → $45 | $30.82 | +46.01% | 17 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $620 → $475 | $403.13 | +17.83% | 24 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $12 | $13.13 | -8.61% | 19 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $140 → $110 | $91.25 | +20.55% | 9 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $77 | $75.76 | +1.64% | 17 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $138 → $115 | $106.93 | +7.55% | 8 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $12 | $8.77 | +36.83% | 11 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $12 → $6 | $6.15 | -2.44% | 9 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $3 → $2 | $1.12 | +78.57% | 4 | May 10, 2024 |
Natera
May 9, 2025
Maintains: Overweight
Price Target: $160 → $190
Current: $151.95
Upside: +25.04%
Certara
May 8, 2025
Upgrades: Overweight
Price Target: $11 → $14
Current: $11.98
Upside: +16.86%
Charles River Laboratories International
May 8, 2025
Maintains: Equal-Weight
Price Target: $145 → $155
Current: $138.79
Upside: +11.68%
Bruker
May 8, 2025
Maintains: Overweight
Price Target: $50 → $46
Current: $37.52
Upside: +22.60%
IQVIA Holdings
May 7, 2025
Maintains: Equal-Weight
Price Target: $170 → $165
Current: $148.99
Upside: +10.75%
ICON Public Limited Company
May 2, 2025
Maintains: Equal-Weight
Price Target: $165 → $155
Current: $133.96
Upside: +15.71%
Exact Sciences
May 2, 2025
Maintains: Overweight
Price Target: $55 → $75
Current: $51.63
Upside: +45.26%
Guardant Health
May 1, 2025
Maintains: Overweight
Price Target: $55 → $60
Current: $41.72
Upside: +43.82%
Avantor
Apr 28, 2025
Maintains: Overweight
Price Target: $18 → $15
Current: $12.02
Upside: +24.79%
Danaher
Apr 22, 2025
Maintains: Overweight
Price Target: $205 → $215
Current: $189.73
Upside: +13.32%
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $400 → $350
Current: $344.06
Upside: +1.73%
Apr 10, 2025
Maintains: Overweight
Price Target: $58 → $45
Current: $30.82
Upside: +46.01%
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $620 → $475
Current: $403.13
Upside: +17.83%
Apr 10, 2025
Maintains: Overweight
Price Target: $16 → $12
Current: $13.13
Upside: -8.61%
Apr 10, 2025
Maintains: Overweight
Price Target: $140 → $110
Current: $91.25
Upside: +20.55%
Apr 10, 2025
Maintains: Underweight
Price Target: $100 → $77
Current: $75.76
Upside: +1.64%
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $138 → $115
Current: $106.93
Upside: +7.55%
Apr 10, 2025
Maintains: Overweight
Price Target: $15 → $12
Current: $8.77
Upside: +36.83%
Apr 10, 2025
Downgrades: Underweight
Price Target: $12 → $6
Current: $6.15
Upside: -2.44%
May 10, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $1.12
Upside: +78.57%